Form 8-K Kymera Therapeutics, For: Jun 25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Form 8-K Kymera Therapeutics, For: Jun 25
June 25, 2025 4:05 PM EDT
Brookline Capital Markets analyst Leah Rush Cann lowered the price target on Kymera Therapeutics (NASDAQ: KYMR) to $70.00 (from $97.00) while maintaining a Buy rating.
The analyst comments "Conclusions Our estimated revenue for 2025 2027 is being reduced resulting from timing of collaboration revenue from Sanofi. We have... More
June 25, 2025 12:43 PM EDT
Jefferies analyst Kelly Shi lowered the price target on Kymera Therapeutics (NASDAQ: KYMR) to $64.00 (from $66.00) while maintaining a Buy rating.
The analyst comments "KYMR announced two updates on parternship: 1) SNY will not advance Ph2 IRAK4 degrader KT-474 in AD/HS and will... More
June 25, 2025 10:32 AM EDT
Stifel analyst Alex Thompson reiterated a Buy rating and $68.00 price target on Kymera Therapeutics (NASDAQ: KYMR), saying they would buy on today's weaknesses related to the updated on the Sanofi IRAK4 collaboration. Shares of KYMR are down 3.7% currently.
The analyst commented, "We are reiterating our Buy Rating on... More
